

Resource Summary Report

Generated by [nidm-terms](#) on Aug 7, 2026

Allele Frequencies in Worldwide Populations

RRID:SCR_007259

Type: Tool

Proper Citation

Allele Frequencies in Worldwide Populations (RRID:SCR_007259)

Resource Information

URL: <http://www.allelefrequencies.net>

Proper Citation: Allele Frequencies in Worldwide Populations (RRID:SCR_007259)

Description: The main purpose of the allelefrequencies.net website is to provide one central source, freely available to all. For the storage of allele frequencies from different polymorphic areas in the HUMAN genome. Users can contribute the results of their work into one common database, and can perform database searches on information already available. They have currently collected data in allele, haplotype and genotype format. The success of this website will depend on you to contribute your data. Sponsors: This resource is supported Royal Liverpool University. Keywords: Allele, Polymorphic, Genome, Database, Data, Haplotype, Genotype,

Synonyms: Allele Frequencies

Resource Type: database, data or information resource

Keywords: bio.tools, FASEB list

Resource Name: Allele Frequencies in Worldwide Populations

Resource ID: SCR_007259

Alternate IDs: r3d100011904, biotools:allele_frequency_net, nif-0000-30079

Alternate URLs: https://bio.tools/allele_frequency_net, <https://doi.org/10.17616/R3F063>

Record Creation Time: 20220129T080240+0000

Record Last Update: 20260807T042651+0000

Ratings and Alerts

No rating or validation information has been found for Allele Frequencies in Worldwide Populations.

No alerts have been found for Allele Frequencies in Worldwide Populations.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 477 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Kasahara S, et al. (2026) Safety and immunogenicity of an adjuvant-free peptide vaccine targeting IL-17A: Phase 1 randomized controlled trial. *iScience*, 29(8), 116817.

Laurenson AJ, et al. (2026) TEpiNom: A computational framework integrating population data to prioritize Plasmodium falciparum T cell epitopes. *Vaccine*, 77, 128388.

Maeding N, et al. (2026) Deep immune-phenotyping of HLA-homozygous iPS-cardiomyocytes by spectral flow cytometry. *Frontiers in immunology*, 17, 1736994.

Fathi S, et al. (2026) Systems Vaccinology-Integrated Proteomics to Develop a Novel Prophylactic and Therapeutic Vaccine Against Human Papillomavirus 16. *Bioinformatics and biology insights*, 20, 11779322261437247.

Shi B, et al. (2026) Mutations of six amino acid residues in a B domain-deleted blood coagulation factor VIII have a cumulative effect on increasing its secretion. *Research and practice in thrombosis and haemostasis*, 10(1), 103325.

Hosseinpour Jahednia S, et al. (2026) Evaluating the effect of immunization with DNA encoding Phlebotomus sergenti apyrase protein (PsSP42) against Leishmania tropica infection in BALB/c mouse model. *Parasites & vectors*, 19(1).

Lestari T, et al. (2026) Molecular Variations in Glycoprotein B of Asian Human Cytomegalovirus: Potential Impact on Virus Entry and Immune Evasion in Ocular Diseases. *Journal of medical virology*, 98(1), e70786.

Wang C, et al. (2026) A Deep Learning-Driven Framework Integrating Organoid-Based Functional Validation Identifies Universal Neoantigens from Recurrent Glioma Mutations. *Cancer research*, 86(12), 3074.

Bao S, et al. (2026) Subgroups based on autoantibody status associated with clinical manifestations, HLA-DRB1 variants, cytokines, and flare of vasculitis in childhood-onset systemic lupus erythematosus. *Frontiers in immunology*, 17, 1766478.

Hinze CH, et al. (2026) No association of HLA-DRB1*15:01 and HLA-DRB1*11 in systemic juvenile idiopathic arthritis-associated macrophage activation syndrome and

other secondary hemophagocytic lymphohistiocytoses. *EULAR rheumatology open*, 2(1), 203.

Montellier E, et al. (2026) Neoantigenic properties of TP53 variants influence cancer risk in individuals with Li-Fraumeni syndrome. *EBioMedicine*, 123, 106065.

Shao H, et al. (2026) KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors. *Science advances*, 12(8), eaea2511.

Versiani AF, et al. (2026) Integrated reiterative pipeline for rapid epitope-based pan-alphavirus vaccines. *Science advances*, 12(11), eaeb2066.

Savostyanova TA, et al. (2026) The guardian of the genome meets immunotherapy: p53-based strategies. *Frontiers in immunology*, 17, 1762679.

Niederschweiberer M, et al. (2026) HLA Associations Differ by Ethnicity and Aquaporin-4 Antibody Status in Patients With Neuromyelitis Optica Spectrum Disorders. *Neurology(R) neuroimmunology & neuroinflammation*, 13(3), e200562.

Campos I, et al. (2026) A fully human IgG1 antibody targeting MICA ?1 domain inhibits interaction with NKG2D and activates immune effector functions against MICA-expressing cells. *Frontiers in immunology*, 17, 1740184.

Enriquez-Vera D, et al. (2026) The viral and host genomic landscape of human T-cell leukemia virus type I in Peru. *Virology journal*, 23(1).

Jerome JR, et al. (2025) Optimisation of the cultured ELISpot/Fluorospot technique for the selective investigation of SARS-CoV-2 reactive central memory T cells. *Frontiers in immunology*, 16, 1547220.

He J, et al. (2025) Constructing a potential HLA haplo-homozygous induced pluripotent stem cell haplobank using data from an umbilical cord blood bank. *Stem cell research & therapy*, 16(1), 42.

Makuch M, et al. (2025) The TNF?-binding domain of the therapeutic antibody adalimumab elicits CD4 T-cell responses in rheumatoid arthritis patients. *Frontiers in immunology*, 16, 1549781.